Questões de Inglês

F.D.A. Panel Votes to Continue Use of Anemia Drugs

ANDREW POLLACK

A federal advisory panel, in response to mounting safety concerns, called Thursday for additional restrictions on the use of anemia drugs by cancer patients.

The recommendation by a committee that advises the Food and Drug Administration could lead to an additional decline in sales for the drugs: Aranesp, made by Amgen, and Procrit, made by Johnson & Johnson.

But the manufacturers avoided the outcome they most feared — a recommendation that the drugs not be used by any cancer patients. That probably would have cost each company at least $1 billion in sales.

"They dodged the really big bullet, but they still took some damage," said Geoffrey C. Porges, a biotechnology analyst at Sanford C. Bernstein & Co.

The F.D.A. is expected to revise the drugs' labels in consultation with the manufacturers. The agency does not have to adhere to the recommendations of its committees, though it usually does.

Patients take the drugs to counter the anemia caused by chemotherapy. The meeting was held because clinical trials have suggested the drugs might worsen some cancers. However, those studies involved doses higher than those typically used by patients.

The companies argued that it was not clear the drugs were dangerous and that they should remain available because they help patients avoid blood transfusions, which carry their own risks.

From: Times Digest, March 14, 2008.

De acordo com o texto acima...

F.D.A. Panel Votes to Continue Use of Anemia Drugs

ANDREW POLLACK

A federal advisory panel, in response to mounting safety concerns, called Thursday for additional restrictions on the use of anemia drugs by cancer patients.

The recommendation by a committee that advises the Food and Drug Administration could lead to an additional decline in sales for the drugs: Aranesp, made by Amgen, and Procrit, made by Johnson & Johnson.

But the manufacturers avoided the outcome they most feared — a recommendation that the drugs not be used by any cancer patients. That probably would have cost each company at least $1 billion in sales.

"They dodged the really big bullet, but they still took some damage," said Geoffrey C. Porges, a biotechnology analyst at Sanford C. Bernstein & Co.

The F.D.A. is expected to revise the drugs' labels in consultation with the manufacturers. The agency does not have to adhere to the recommendations of its committees, though it usually does.

Patients take the drugs to counter the anemia caused by chemotherapy. The meeting was held because clinical trials have suggested the drugs might worsen some cancers. However, those studies involved doses higher than those typically used by patients.

The companies argued that it was not clear the drugs were dangerous and that they should remain available because they help patients avoid blood transfusions, which carry their own risks.

From: Times Digest, March 14, 2008.

De acordo com o texto acima...

F.D.A. Panel Votes to Continue Use of Anemia Drugs

ANDREW POLLACK

A federal advisory panel, in response to mounting safety concerns, called Thursday for additional restrictions on the use of anemia drugs by cancer patients.

The recommendation by a committee that advises the Food and Drug Administration could lead to an additional decline in sales for the drugs: Aranesp, made by Amgen, and Procrit, made by Johnson & Johnson.

But the manufacturers avoided the outcome they most feared — a recommendation that the drugs not be used by any cancer patients. That probably would have cost each company at least $1 billion in sales.

"They dodged the really big bullet, but they still took some damage," said Geoffrey C. Porges, a biotechnology analyst at Sanford C. Bernstein & Co.

The F.D.A. is expected to revise the drugs' labels in consultation with the manufacturers. The agency does not have to adhere to the recommendations of its committees, though it usually does.

Patients take the drugs to counter the anemia caused by chemotherapy. The meeting was held because clinical trials have suggested the drugs might worsen some cancers. However, those studies involved doses higher than those typically used by patients.

The companies argued that it was not clear the drugs were dangerous and that they should remain available because they help patients avoid blood transfusions, which carry their own risks.

From: Times Digest, March 14, 2008.

De acordo com o texto acima...

F.D.A. Panel Votes to Continue Use of Anemia Drugs

ANDREW POLLACK

A federal advisory panel, in response to mounting safety concerns, called Thursday for additional restrictions on the use of anemia drugs by cancer patients.

The recommendation by a committee that advises the Food and Drug Administration could lead to an additional decline in sales for the drugs: Aranesp, made by Amgen, and Procrit, made by Johnson & Johnson.

But the manufacturers avoided the outcome they most feared — a recommendation that the drugs not be used by any cancer patients. That probably would have cost each company at least $1 billion in sales.

"They dodged the really big bullet, but they still took some damage," said Geoffrey C. Porges, a biotechnology analyst at Sanford C. Bernstein & Co.

The F.D.A. is expected to revise the drugs' labels in consultation with the manufacturers. The agency does not have to adhere to the recommendations of its committees, though it usually does.

Patients take the drugs to counter the anemia caused by chemotherapy. The meeting was held because clinical trials have suggested the drugs might worsen some cancers. However, those studies involved doses higher than those typically used by patients.

The companies argued that it was not clear the drugs were dangerous and that they should remain available because they help patients avoid blood transfusions, which carry their own risks.

From: Times Digest, March 14, 2008.

De acordo com o texto acima...

F.D.A. Panel Votes to Continue Use of Anemia Drugs

ANDREW POLLACK

A federal advisory panel, in response to mounting safety concerns, called Thursday for additional restrictions on the use of anemia drugs by cancer patients.

The recommendation by a committee that advises the Food and Drug Administration could lead to an additional decline in sales for the drugs: Aranesp, made by Amgen, and Procrit, made by Johnson & Johnson.

But the manufacturers avoided the outcome they most feared — a recommendation that the drugs not be used by any cancer patients. That probably would have cost each company at least $1 billion in sales.

"They dodged the really big bullet, but they still took some damage," said Geoffrey C. Porges, a biotechnology analyst at Sanford C. Bernstein & Co.

The F.D.A. is expected to revise the drugs' labels in consultation with the manufacturers. The agency does not have to adhere to the recommendations of its committees, though it usually does.

Patients take the drugs to counter the anemia caused by chemotherapy. The meeting was held because clinical trials have suggested the drugs might worsen some cancers. However, those studies involved doses higher than those typically used by patients.

The companies argued that it was not clear the drugs were dangerous and that they should remain available because they help patients avoid blood transfusions, which carry their own risks.

From: Times Digest, March 14, 2008.

De acordo com o texto acima...

A questão refere-se ao seguinte texto:

Ethical abuses in the authorship of scientific papers

Problems regarding the order of authorship of scientific papers have become more frequent and more abusive. These problems may have heightened due to the ever increasing pressure to “publish or perish” in the academic world, given that the publication of scientific articles has become the benchmark of success in a field with few job opportunities. This article reviews the abuses in the authorship of scientific papers. Different examples are given of the most common problems and recommendations are provided for authors and journal editors.

Rev. Bras. Entomol. Vol. 51 no. 1 São Paulo, Jan./Mar. 2007